Accelerating drug development by early unwanted immunogenicity testing

About the webinar

Complex immune responses elicited upon treatment with biotherapeutic drugs are now revolutionizing the field of immuno-oncology. However, unwanted immune responses exerted by biologics can result in severe adverse effects. Immunogenicity testing at the early phase of drug development therefore can play a crucial role to avoid possible clinical consequences of anti-drug antibody (ADA) responses. Testing unwanted immune responses during drug development is becoming increasingly important for pharmaceutical industries and regulatory agencies like the FDA and EMEA.   

This webinar covers:  

• Causes and consequences of unwanted immunogenicity
• In vitro cellular assays to assess unwanted immunogenicity, including T cell activation/proliferation and MAPPS (MHC-associated peptide proteomics) assays
• Strategies to manage and reduce unwanted immune responses